Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Molecular Innate Immunity

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1661679

This article is part of the Research TopicImmune Landscape in the Transition from Inflammation to TumorigenesisView all 7 articles

Integrative Modeling of Malignant Epithelial Programs in EGFR-Mutant LUAD via Single-Cell Transcriptomics and Multi-Algorithm Machine Learning

Provisionally accepted
  • 1Tianjin Chest Hospital, Tianjin, China
  • 2Qingdao Municipal Hospital Group, Qingdao, China
  • 3Tianjin University, Tianjin, China

The final, formatted version of the article will be published soon.

Abstract Background Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer, with EGFR mutations serving as key oncogenic drivers. However, patients harboring EGFR mutations exhibit considerable heterogeneity in clinical outcomes and treatment responses. Characterizing the malignant features of EGFR-mutant epithelial cells may facilitate improved stratification and personalized therapeutic strategies. Methods Using publicly available single-cell RNA sequencing data, malignant epithelial cells were identified in EGFR-mutant LUAD samples via inferCNV and k-means clustering. Pseudotime trajectories were constructed using Monocle2, and branch-specific genes were extracted for functional analysis. Differentially expressed genes were integrated with TCGA bulk transcriptomic data, and ten machine learning algorithms were applied to construct the EGFR Mutation-Associated Malignant Epithelial Cell-Related Signature (EGFRmERS). The prognostic value of EGFRmERS was validated across multiple independent cohorts. Associations between EGFRmERS and immune infiltration, immunotherapy response, tumor mutation burden (TMB), and copy number variations (CNVs) were systematically assessed. The performance of EGFRmERS was also benchmarked against previously published LUAD prognostic signatures. Finally, the core gene PERP was selected for in vitro functional validation, including qRT-PCR, Transwell migration/invasion, and colony formation assays. Results EGFR-mutant epithelial cells were classified into subclusters with varying malignant potential, enriched in pathways such as cell cycle regulation and DNA repair. The EGFRmERS signature robustly predicted patient prognosis across multiple cohorts and outperformed existing models. High EGFRmERS scores were associated with an immunosuppressive microenvironment, reduced immunotherapy responsiveness (as indicated by TIDE and IPS scores), elevated TMB, and increased genomic instability. PERP was identified as a key gene, highly expressed in LUAD and associated with poor prognosis. Functional assays confirmed its role in promoting cell migration, invasion, and clonogenic capacity. Conclusions This study delineates key malignant programs in EGFR-mutant epithelial cells at the single-cell level and proposes a robust prognostic scoring system, EGFRmERS, with strong predictive power for survival and immunotherapy benefit. PERP was identified as a potential therapeutic target, offering novel insights for precision stratification and treatment in EGFR-mutant LUAD.

Keywords: LUAD1, scRNA-seq2, EGFR3, machine learning4, immunotherapy5, PERP6

Received: 08 Jul 2025; Accepted: 20 Aug 2025.

Copyright: © 2025 Weiran, Lin, Mu, Zhang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Daqiang Sun, Tianjin Chest Hospital, Tianjin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.